Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab vs Chemotherapy in Pleural Mesothelioma
NCT05136677Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in malignant pleural mesothelioma (MPM), sponsored by Bristol Myers Squibb. Started Jan 2022; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05136677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136677.